Struggles in Full Biomarker Testing for Lung Cancer

LYNETTE M. SHOLL, MD
Thursday, April 16, 2020


With minimally invasive procedures to test lung cancer tumors, there often isn't enough tissue to undergo a full biomarker test, pointing toward the strength of liquid biopsies, explained Lynette M. Sholl, MD, chief of thoracic pathology at Brigham and Women's Hospital, Dana-Farber Cancer Institute, and associate professor at Harvard Medical School.

Transcription

One of the biggest challenges we face in the lung cancer space is availability of tissue for complete biomarker characterization. Many times, patients will undergo minimally invasive procedures to get diagnostic tissue. Those are typically very small biopsies. I think the great thing about minimally invasive procedures is that they're minimally invasive and they have a relatively small number of adverse effects for the patients in terms of bleeding or other complications.

But the downside, of course, is that you don't get very much material to work with. So you have a little bit of material to make your diagnosis and then you try to squeeze a lot more information out of those tissues. We end up seeing somewhere around 30% of tissue biopsies actually being insufficient to generate complete biomarker testing in our lung cancer patients. That's really where I think the strength of liquid biopsies emerges.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.